PL4243828T3 - Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych - Google Patents

Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych

Info

Publication number
PL4243828T3
PL4243828T3 PL21835890.1T PL21835890T PL4243828T3 PL 4243828 T3 PL4243828 T3 PL 4243828T3 PL 21835890 T PL21835890 T PL 21835890T PL 4243828 T3 PL4243828 T3 PL 4243828T3
Authority
PL
Poland
Prior art keywords
inhibitor
compositions
methods
solid tumors
krasg12c
Prior art date
Application number
PL21835890.1T
Other languages
English (en)
Inventor
Marie Evangelista
Mark Andrew MERCHANT
Jennifer Lee SCHUTZMAN
Ting-Kun Mark LIN
Stephanie Royer JOO
Sandhya Vinayak MANDLEKAR
Stuart G. LUTZKER
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL4243828T3 publication Critical patent/PL4243828T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL21835890.1T 2020-11-13 2021-11-11 Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych PL4243828T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063113609P 2020-11-13 2020-11-13
PCT/US2021/058877 WO2022103905A1 (en) 2020-11-13 2021-11-11 Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors

Publications (1)

Publication Number Publication Date
PL4243828T3 true PL4243828T3 (pl) 2025-06-23

Family

ID=79185775

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21835890.1T PL4243828T3 (pl) 2020-11-13 2021-11-11 Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych

Country Status (13)

Country Link
US (2) US12016862B2 (pl)
EP (1) EP4243828B1 (pl)
JP (1) JP2023550028A (pl)
KR (1) KR20230088781A (pl)
CN (1) CN116568326A (pl)
AU (2) AU2021377810B2 (pl)
CA (1) CA3201521A1 (pl)
ES (1) ES3032036T3 (pl)
IL (1) IL301293A (pl)
MX (1) MX2023005529A (pl)
PL (1) PL4243828T3 (pl)
TW (2) TWI886356B (pl)
WO (1) WO2022103905A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103905A1 (en) * 2020-11-13 2022-05-19 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
CN119013026A (zh) 2022-04-06 2024-11-22 基因泰克公司 用于治疗癌症的包含gdc-6036和gdc-0077的组合疗法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CZ291047B6 (cs) 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
KR100856995B1 (ko) 1997-04-07 2008-09-04 제넨테크, 인크. 인간화 항체 및 인간화 항체의 제조 방법
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN111867591A (zh) * 2018-02-12 2020-10-30 Array生物制药公司 治疗胆道癌的方法和组合疗法
PL3735299T3 (pl) * 2018-11-09 2025-01-27 F. Hoffmann-La Roche Ag Związki o pierścieniach skondensowanych
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2022103905A1 (en) * 2020-11-13 2022-05-19 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors

Also Published As

Publication number Publication date
CN116568326A (zh) 2023-08-08
AU2025201610A1 (en) 2025-03-27
US12016862B2 (en) 2024-06-25
EP4243828B1 (en) 2025-04-02
AU2021377810A1 (en) 2023-05-11
CA3201521A1 (en) 2022-05-19
TWI886356B (zh) 2025-06-11
ES3032036T3 (en) 2025-07-15
TW202224682A (zh) 2022-07-01
JP2023550028A (ja) 2023-11-30
AU2021377810B2 (en) 2025-01-02
KR20230088781A (ko) 2023-06-20
EP4243828A1 (en) 2023-09-20
MX2023005529A (es) 2023-05-25
US12409178B2 (en) 2025-09-09
US20220152030A1 (en) 2022-05-19
US20240299392A1 (en) 2024-09-12
IL301293A (en) 2023-05-01
TW202535399A (zh) 2025-09-16
WO2022103905A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
IL272877A (en) SHP2 inhibitory compositions and methods for cancer treatment
PT4181920T (pt) Inibidor de kat6 e combinações para o tratamento do cancro da mama
IL286350A (en) Preparations and methods for the treatment of cancer
ZA202006627B (en) Methods and compositions for treating cancer
SG11202009793TA (en) Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
ZA202104870B (en) Methods and compositions for treating cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
EP4025590A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL285796A (en) Methods and preparations for the treatment of cancer
IL287982A (en) Preparations and methods for the treatment of cancer
SG11202012435UA (en) Compositions and methods for treating cancer
PL4243828T3 (pl) Sposoby i kompozycje zawierające inhibitor KRasG12C i inhibitor VEGF do leczenia nowotworów litych
IL287865A (en) Pde9 inhibitors for treating thalassemia
EP4077690A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
IL315800A (en) Preparations and methods for the treatment of cancer
IL309120A (en) Methods and compositions for the treatment of cancer
IL309071A (en) Methods and compositions for the treatment of cancer
SG11202010911WA (en) Methods and compositions for treating chronic urticaria
EP4069253A4 (en) METHOD AND COMPOSITIONS FOR TREATING GLIOBLASTOMA
IL285828B2 (en) Compounds for the treatment and prevention of complications associated with extracellular neutrophil traps
IL319403A (en) Compositions and methods for treating advanced solid tumors
IL312846A (en) Methods and preparations for the treatment of cancer
IL285036A (en) Methods and preparations for the treatment of cancer
KR102349013B9 (ko) 멜라토닌을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102479523B9 (ko) Cotl1 억제제를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물